类似胰岛素的增长因子结合蛋白-6调节孕激素对乳腺癌的反应中的增殖对抗性
Francisco J Lariz1, Pacha B Botero1, Isabella Shoffstall1
1New Mexico State University, Department of Chemistry and Biochemistry, Las Cruces, NM, United States.
Frontiers in endocrinology
|December 19, 2024
概括
高水平的胰岛素样生长因子结合蛋白6 (IGFBP-6) 提高了孕激素受体阳性乳腺癌的存活率. IGFBP-6调节孕激素的作用,而孕激素受体 (PR) 对其保护作用至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 乳腺癌是全球领先的癌症诊断.
- 由IGF结合蛋白 (IGFBPs) 调节的胰岛素样生长因子 (IGF) 系统,影响乳腺癌细胞的增殖和存活.
- IGFBP-6在激素受体阳性乳腺癌中的作用尚不清楚.
研究的目的:
- 研究IGFBP-6在激素受体阳性乳腺癌中的作用.
- 确定IGFBP-6表达和患者存活率之间的关系.
- 阐明IGFBP-6在调节孕激素受体 (PR) 作用中的功能机制.
主要方法:
- 使用公共数据库进行生存分析.
- 研究由孕激素在T47D乳腺癌细胞中的IGFBP-6转录诱导.
- 在乳腺癌细胞系 (T47D和MCF-7) 中进行基因淘汰和过度表达研究.
- 对关键蛋白质和细胞循环调节者的分析 (PR-A,PR-B,p21,Cyclin E2,EGFR).
主要成果:
- 高IGFBP-6水平与孕激素受体阳性乳腺癌患者的整体存活率改善相关.
- 孕激素诱导IGFBP-6在T47D细胞中的表达.
- 降低IGFBP-6降低了孕激素的抗增殖作用,并改变了PR异形水平.
- 过度表达IGFBP-6会增加EGFR的表达,而激素刺激会进一步增强这种表达.
- 孕激素诱导的p21表达依赖于IGFBP-6,而Cyclin E2诱导仅发生在IGFBP-6敲击时.
结论:
- 在乳腺癌中,IGFBP-6作为孕激素作用的调节剂.
- 孕激素受体 (PR) 对于IGFBP-6的保护作用至关重要.
- 在激素受体阳性乳腺癌中,IGFBP-6是潜在的治疗标或生物标记物.
相关概念视频
Target Cell Response to Hormones
2.9K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
2.9K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


